Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 500a (miR-500a) is a small, non-coding RNA molecule that functions as a post-transcriptional regulator of gene expression by binding to complementary sequences in target messenger RNAs. miR-500a exists in both -5p and -3p mature forms, and its expression has been implicated in several biological processes and diseases. In particular, miR-500a-5p modulates oxidative stress response genes and is upregulated in some breast cancer cell lines, especially those that are estrogen receptor positive. It influences the progression of breast cancer and may serve as a prognostic biomarker in this context. Like other microRNAs, miR-500a does not encode proteins but exerts its activity primarily through sequence-specific interaction with mRNA targets, leading to their degradation or translational repression[1][4].
Not directly applicable, as microRNAs generally function by binding to complementary sequences in target mRNAs and causing their degradation or inhibition of translation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 500a (miR-500a).